The present invention provides a new crystal form of a N-phenyl-2-aminopyrimidine compound, a crystal form of a pharmaceutically acceptable salt of said compound, and a preparation method for these crystal forms and use thereof. The present invention also relates to a pharmaceutical composition and a pharmaceutical preparation comprising the crystal form of said compound and the crystal form of the pharmaceutically acceptable salt of said compound, and use of these crystal forms, the pharmaceutical composition and the pharmaceutical preparation for treating diseases or conditions associated with the cell epidermal growth factor receptor (EGFR), for example, for treating or improving abnormal cell proliferative conditions, such as cancer.